Orikine Bio is a spin-off from the Centre for Genomic Regulation (CRG) in Barcelona, developing a unique synthetic biology platform that delivers optimized and novel engineered cytokines called Foldikines^©.

Cytokines are proteins that are produced by the immune system and act as soluble messengers that control the entire range of immune responses, including their initiation, type, potency, and duration. Thus, dysregulated cytokine signalling triggers a wide variety of inflammatory and autoimmune diseases, allergies, fibrosis, and cancer.

Orikine Bio’s Foldikines^© have unique biological activities that are not available for natural cytokines, making them highly attractive as new drugs for therapeutic interventions. The initial focus of the company is to advance these improved cytokines into clinical development for new therapies targeting autoimmune and inflammatory diseases.